|1.||Grothues, F: 2 articles (12/2008 - 01/2007)|
|2.||Wible, James H: 2 articles (02/2008 - 12/2007)|
|3.||Napoli, Alicia: 2 articles (02/2008 - 11/2006)|
|4.||Banderali, Giuseppe: 1 article (08/2014)|
|5.||David, Vincenzo: 1 article (08/2014)|
|6.||Guastalla, Pierpaolo: 1 article (08/2014)|
|7.||Stacul, Fulvio: 1 article (08/2014)|
|8.||Quaranta, Roberto: 1 article (08/2014)|
|9.||Zuppa, Antonio Alberto: 1 article (08/2014)|
|10.||Cova, Maria Assunta: 1 article (08/2014)|
02/05/2008 - "Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial."
12/01/2008 - "Safety of gadoversetamide in patients with acute and chronic myocardial infarction."
11/01/2006 - "Eighteen patients with acute myocardial infarction (AMI) were randomly divided into three groups according to the dose of gadoversetamide (0.1, 0.2, or 0.3 mmol/kg) administered. "
12/01/2008 - "To assess the safety data from two large, multicenter, phase 2 trials on the use of gadoversetamide (OptiMARK, Tyco Healthcare/Mallinckrodt, St. Louis, MO) as a contrast agent in delayed hyperenhancement magnetic resonance imaging (DE-MRI) in patients with acute and chronic myocardial infarction (MI). "
|2.||Body Weight (Weight, Body)
01/01/2007 - "As part of a Phase 2 multi-center dose ranging study for infarct identification patients received 1 of 4 possible dosages (0.05, 0.1, 0.2 or 0.3 mmol/kg body weight) of the contrast agent gadoversetamide (OptiMARK, Tyco Healthcare Mallinckrodt, St. Louis, MO, USA). "
07/01/2010 - "The principal gadolinium(III) complex in a rat kidney tissue extract was identified as Gd-DTPA-BMEA 24 Hrs and 7 days after a single intravenous injection of Optimark™ (gadoversetamide; Gd-DTPA-BMEA) at a dose of 5 mmol Gd/kg body weight. "
|3.||Nephrogenic Fibrosing Dermopathy
01/01/2009 - "Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate."
12/01/2009 - "In patients with impaired renal function and nephrogenic systemic fibrosis (NSF), the agents gadodiamide, gadoversetamide, and gadopentetate dimeglumine have been shown to result in Gd deposition in the skin and internal organs. "
08/01/2014 - "Breastfeeding is safe for the nursing infant of any post-conceptional age after administration of the majority of radiological contrast media to the mother; only gadolinium-based agents considered at high risk of nephrogenic systemic fibrosis (gadopentetate dimeglumine, gadodiamide, gadoversetamide) should be avoided in the breastfeeding woman as a precaution; there is no need to temporarily discontinue breastfeeding or to express and discard breast milk following the administration of contrast media assessed as compatible with breastfeeding. "
10/01/2012 - "Nephrogenic systemic fibrosis (NSF) has been reported in humans to be most likely induced by gadolinium based contrast agents (GBCA), namely by gadodiamide, gadopentetate dimeglumine, and gadoversetamide, rarely by other GBCA. "
09/01/2007 - "Information was obtained from PubMed, International Pharmaceutical Abstracts, Iowa Drug Information Service, and Google Scholar, using the unlimited search terms nephrogenic systemic fibrosis, NSF, nephrogenic fibrosing dermopathy, NFD, gadolinium, gadodiamide, gadoversetamide, gadopentetate, gadobenate, and gadoteridol. "
03/01/2008 - "Approximately 20% of patients receiving gadoversetamide exhibited spurious hypocalcemia. "
10/01/2004 - "Spurious hypocalcemia after Omniscan- or OptiMARK-enhanced magnetic resonance imaging: an algorithm for minimizing a false-positive laboratory value."
12/01/2007 - "However, the orthocresolphthalein method of measuring serum calcium produced a transient hypocalcemia artifact in the presence of gadoversetamide or gadodiamide."
|5.||Renal Insufficiency (Renal Failure)
02/01/1999 - "The pharmacokinetic parameters, safety, and tolerability of OptiMARK (gadoversetamide injection), a gadolinium-based magnetic resonance imaging (MRI) contrast agent, were evaluated in 163 subjects with either central nervous system (CNS) or liver pathology with and without renal insufficiency, for which a contrast-enhanced MRI was indicated. "
|2.||Gadolinium DTPA (Magnevist)
|9.||gadobenic acid (gadobenate dimeglumine)